An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England

Trial Profile

An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Asenapine (Primary)
  • Indications Bipolar I disorders
  • Focus Adverse reactions
  • Acronyms OBSERVA
  • Most Recent Events

    • 27 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 25 Jan 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2017, as reported by ClinicalTrials.gov.
    • 25 Jan 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top